Oncology · Supportive CareRegulatory Approvalregulatorymid-term

Hikma's Leucovorin Calcium ANDA072736 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma28 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:33:01 PM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Hikma's receipt of Abbreviated Approval (AP) status for Leucovorin Calcium is significant as it strengthens their competitive position in the oncology supportive care market. This development necessitates a reassessment of market strategies by other players in the space to maintain their market share and competitive edge. Regulatory context from FDA (FDA AP — LEUCOVORIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for Leucovorin Calcium and consider strategic positioning against existing therapies. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · Supportive Care, 8 regulatory and 4 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This approval may enhance Hikma's position in the oncology supportive care market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEUCOVORIN CALCIUM (SUPPL) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). The AP status indicates a streamlined pathway for Hikma's product, which may influence the regulatory strategies of competitors and their timelines for market entry.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Hikma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The approval could lead to increased market share for Hikma, potentially affecting revenue streams for competitors offering similar supportive care therapies.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for Hikma may improve if Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study. (PubMed) delivers favorable follow-through.
Upside for Hikma may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor for market entry timelines and any potential competitive responses from other manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Restraints in Intensive Care Unit Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Data Collection, Clinical Care and Interventions in CCR, NCI
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Reducing Disparities in Behavioral Health Treatment for Children in Primary Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nurses' perspectives on medication safety for Swedish community-dwelling older adults in primary care.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
competitors with similar products

Commercial impact

medium

The approval could lead to increased market share for Hikma, potentially affecting revenue streams for competitors offering similar supportive care therapies.

Regulatory impact

medium

The AP status indicates a streamlined pathway for Hikma's product, which may influence the regulatory strategies of competitors and their timelines for market entry.

What to watch

Monitor for market entry timelines and any potential competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.